Publications by authors named "Julia Piasecki"

Claim this Profile
C
Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Fan Wu, Xirong Zheng, Joseph Burnett, Madhan Masilamani, Wanying Zhang, Julia Piasecki

J Clin Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Cellular Kinetics of Idecabtagene Vicleucel in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Fan Wu, Jian Zhou, Xirong Zheng, Madhan Masilamani, Yiming Cheng, Julia Piasecki

Clin Pharmacokinet· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma.
Hongxiang Hu, Yan Li, Julia Piasecki, Daniela Hosseyni, Zhicheng Yan

Clin Cancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K Nooka, Julia Piasecki

Blood· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
Paula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Julia Piasecki

Future Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Paula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Julia Piasecki

N Engl J Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local Delivery of OncoVEX Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade.
Achim K Moesta, Keegan Cooke, Julia Piasecki, Petia Mitchell, James B Rottman

Clin Cancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity.
Jonathan D Graves, Jennifer J Kordich, Tzu-Hsuan Huang, Julia Piasecki, Tammy L Bush

Cancer Cell· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
Pamela M Holland, Robert Miller, Jon Jones, Heather Douangpanya, Julia Piasecki

Cancer Biol Ther· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of transgene-specific cytotoxic T lymphocyte responses after transplantation of gene-modified CD34+ cells despite nonablative immunosuppressive conditioning.
Julia C Piasecki, Karen Beagles, Brian C Beard, Stanley Riddell, Hans-Peter Kiem

Hum Gene Ther· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis